Improved sequencing technologies offer unprecedented opportunities for investigating the role of rare genetic variation in common disease. However, there are considerable challenges with respect to study design, data analysis and replication 1 . Using pooled nextgeneration sequencing of 507 genes implicated in the repair of DNA in 1,150 samples, an analytical strategy focused on proteintruncating variants (PTVs) and a large-scale sequencing casecontrol replication experiment in 13,642 individuals, here we show that rare PTVs in the p53-inducible protein phosphatase PPM1D are associated with predisposition to breast cancer and ovarian cancer. PPM1D PTV mutations were present in 25 out of 7,781 cases versus 1 out of 5,861 controls (P 5 1.12 3 10 25 ), including 18 mutations in 6,912 individuals with breast cancer (P 5 2.42 3 10
& Nazneen Rahman 1, 30 Improved sequencing technologies offer unprecedented opportunities for investigating the role of rare genetic variation in common disease. However, there are considerable challenges with respect to study design, data analysis and replication 1 . Using pooled nextgeneration sequencing of 507 genes implicated in the repair of DNA in 1,150 samples, an analytical strategy focused on proteintruncating variants (PTVs) and a large-scale sequencing casecontrol replication experiment in 13,642 individuals, here we show that rare PTVs in the p53-inducible protein phosphatase PPM1D are associated with predisposition to breast cancer and ovarian cancer. PPM1D PTV mutations were present in 25 out of 7,781 cases versus 1 out of 5,861 controls (P 5 1.12 3 10 25 ), including 18 mutations in 6,912 individuals with breast cancer (P 5 2.42 3 10
24
) and 12 mutations in 1,121 individuals with ovarian cancer (P 5 3.10 3 10
29
). Notably, all of the identified PPM1D PTVs were mosaic in lymphocyte DNA and clustered within a 370-base-pair region in the final exon of the gene, carboxy-terminal to the phosphatase catalytic domain. Functional studies demonstrate that the mutations result in enhanced suppression of p53 in response to ionizing radiation exposure, suggesting that the mutant alleles encode hyperactive PPM1D isoforms. Thus, although the mutations cause premature protein truncation, they do not result in the simple loss-of-function effect typically associated with this class of variant, but instead probably have a gain-of-function effect. Our results have implications for the detection and management of breast and ovarian cancer risk. More generally, these data provide new insights into the role of rare and of mosaic genetic variants in common conditions, and the use of sequencing in their identification.
There is strong evidence that rare genetic variation is important in breast and ovarian cancer predisposition 2, 3 . In the 1990s, genome-wide linkage analysis and positional cloning led to the identification of the DNA repair genes BRCA1 and BRCA2, rare mutations of which confer substantial risks of both diseases 2, 3 . More recently, through casecontrol resequencing studies of candidate genes we, and others, have discovered rare variants that confer moderate risks of breast and/or ovarian cancer [4] [5] [6] [7] [8] [9] [10] . These cancers are therefore exemplars of the rare variant, common disease hypothesis.
The successful studies so far have focused on genes encoding proteins involved in DNA repair such as PALB2, ATM, CHEK2, BRIP1, RAD51C and RAD51D (refs 4-10) . These genes are characterized by several, very rare, loss-of-function mutations, usually PTVs, which predispose carriers to breast and/or ovarian cancer [4] [5] [6] [7] [8] [9] [10] . To investigate the role of DNA repair genes in cancer susceptibility further, we sequenced 507 genes (the 'DNA repair panel') in 1,150 individuals with breast cancer from the United Kingdom, 69 of whom also had ovarian cancer (Supplementary Tables 1 and 2 and Supplementary Fig. 1 ). To maximize time, sample and cost efficiency we used a pooled approach combining 200 ng of DNA from each of the 24 individuals into a single pool that we hybridized to a custom pull-down containing the DNA repair panel (Supplementary Table 2 ). We performed sequencing using an Illumina HiSeq2000 sequencer that generated a minimum coverage per pool of 4803 for at least 90% of the target region ( Supplementary Fig. 2 ). Sequence variants were called using Syzygy 11 , the performance of which was evaluated using previously generated data in a subset of the samples. The sensitivity of base substitution calling was 99.6% (439 out of 439 common variants and 24 out of 26 rare variants that were present in 1 out of 24 individuals in a pool). The sensitivity of insertion/deletion calling was 94.4% (51 out of 54 rare insertions/deletions present in 1 out of 24 individuals in a pool; Supplementary Table 3) .
We next considered the 34,564 sequence variants called by Syzygy. We first focused on PTVs because of the strong association of this class of mutation with disease. In total, 1,044 PTVs were called by Syzygy and we used a PTV prioritization method to stratify the genes according to the number of different, rare truncating mutations present within the samples 12 . PPM1D showed the strongest signal in this analysis, and we confirmed by Sanger sequencing that five individuals carried different PPM1D PTVs. Two of these individuals had ovarian cancer in addition to breast cancer.
To explore the role of PPM1D in breast and ovarian cancer susceptibility further, we next performed a case-control Sanger sequencing analysis of PPM1D in a total of 13,642 individuals-7,781 unrelated individuals with breast and/or ovarian cancer and 5,861 population controls (Supplementary Table 1) . We initially sequenced all PPM1D exons and intron-exon boundaries, but after completing this analysis in 3,803 samples we noted that all 10 PTV mutations identified occurred within the last exon of PPM1D, and this clustering was highly significant (P 5 8.2 3 10
26
). We thus analysed the remaining 9,839 samples for this mutation cluster region, identifying a further 16 PTVs (Supplementary Table 1 and Fig. 1 ). In total, we identified 25 PPM1D PTVs in individuals with breast and/or ovarian cancer and 1 in controls (P 5 1.12 3 10
25
; Figs 1 and 2a and Supplementary Table 4 ). This included 18 mutations in 6,912 individuals with breast cancer (P 5 2.42 3 10
24
29
). The histological features of the cancers in PPM1D-mutation carriers were diverse, and five individuals had both breast and ovarian cancer (Supplementary Table 5 ). The case series included 773 individuals with mutations in BRCA1 or BRCA2 (termed BRCA1/2-mutation carriers), four of whom also carried PTVs in PPM1D (4 out 773 versus 1 out of 5,861 controls, P 5 8.30 3 10 24 ). We also identified a total of 16 non-synonymous, 14 synonymous and 1 intronic variant across the cases and controls; there was no evidence for an association with cancer for these variant classes (Supplementary Table 6 ).
The Sanger sequencing chromatograms for the PPM1D PTVs were unusual for heterozygous mutations as the mutant allele was considerably and consistently lower than the wild-type allele, suggesting the mutations were mosaic in lymphocyte DNA ( Fig. 2a and Supplementary Fig. 3 ). This contrasted with the non-truncating variants 
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that all had normal sequencing profiles. DNA from saliva was available for two individuals and the PTVs were present at similar amplitude to that identified in the corresponding blood-derived DNA (Supplementary Fig. 3 ). To confirm that the PTV mutations were bona fide we used two other mutation detection methods: deep PCR amplicon sequencing 13 ( Fig. 2b, Supplementary Fig. 4 and Supplementary Table 4 ) and multiplex ligation-dependent probe amplification (MLPA) 14 (Supplementary Fig. 5 and Supplementary Table 7 ). For the deep PCR amplicon sequencing we generated Nextera libraries of pooled PCR products covering BRCA1, BRCA2 and the PPM1D mutation, which we sequenced using an Illumina MiSeq sequencer generating a median coverage of 3,3873 across the PPM1D mutation ( Supplementary Fig. 4 and Supplementary Table 4 ). This confirmed that the PPM1D PTVs were present at a lower proportion than heterozygous polymorphisms in BRCA1 and BRCA2, with a median mutant read percentage of 16% (range 5-34%). Furthermore, we sequenced the original DNA repair panel in six cases individually (that is, unpooled), which again confirmed the mutations were present, but mosaic ( Supplementary Fig. 6 and Supplementary Table 4 ). For three samples we had data from both the deep PCR amplicon sequencing and the DNA repair panel that gave identical mutation percentage results (Supplementary Table 4) . Finally, family studies were also consistent with mosaicism; none of the 14 relatives carried the PPM1D mutation identified in the proband. Most compellingly, for each of probands 17 and 24, we identified two offspring that had inherited different maternal haplotypes at the PPM1D locus, but neither offspring carried the relevant maternal PPM1D mutation, demonstrating that the mutations were either not present or mosaic in the germline of the probands (Fig. 2c) .
PPM1D (protein phosphatase, Mg 21 /Mn 21 dependent 1D; also known as wild-type p53-induced phosphatase 1 or Wip1) was first identified in a screen for p53 target genes induced by ionizing radiation 15 . PPM1D encodes a 605-amino-acid protein with an aminoterminal phosphatase catalytic domain and a C-terminal domain that contains a putative nuclear localization signal 16 ( Fig. 1) . PPM1D transcription is upregulated in response to various types of DNA damage in a p53-dependent manner. Once upregulated, PPM1D has been shown to dephosphorylate and downregulate several targets, particularly proteins associated with the DNA damage response (DDR) pathway initiated by the ATM (ataxia telangiectasia mutated) or ATR (ATMand Rad3-related) protein kinases, and including tumour suppressors with a proven role in cancer susceptibility such as p53 (ref. 17) , ATM 18 and CHK2 (ref. 19 ). Thus, it has been proposed that a primary role of PPM1D is as a homeostatic regulator of the DDR pathway, facilitating return of cells to their normal state after repair of damaged DNA 17 .
There is also accumulating evidence that PPM1D is involved in oncogenesis 16 . PPM1D amplification and overexpression have been demonstrated in several human tumours 20 , including breast cancers 21 and ovarian clear cell carcinoma 22 , and is a promising therapeutic target [22] [23] [24] . 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 1,000 1,500 2,000 2,500 3,000 3,500 4,000 showing heterozygous BRCA1/2 variants at 50% (open dots), whereas the PPM1D mutation is present at a lower percentage (red dots). c, Haplotype analysis in two families. The offspring of PPM1D-mutation carriers have different maternal haplotypes spanning PPM1D (highlighted), but neither of them carries the mutation, indicating that it is either not present, or mosaic in the germline of the proband.
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The clustering of PTVs within the 370-base-pair (bp) region corresponding to amino acids 420-546, which is downstream of the phosphatase catalytic domain but precedes or disrupts the nuclear localization signal 25 , suggests the PTVs are not acting as simple loss-of-function mutations ( Fig. 1) . Moreover, all the PTVs were in the last exon and thus predicted to evade nonsense-mediated RNA decay and result in a truncated protein that retains the phosphatase catalytic domain, rather than in haploinsufficiency 25, 26 . We confirmed this experimentally for three mutations (Fig. 2a) . To investigate the effect of PPM1D PTVs we generated complementary DNA expression constructs representing two mutant alleles (PPM1D c.1384C.T, case 6, and PPM1D c.1420delC, case 7) and tested their ability to suppress p53 activation in response to ionizing radiation exposure. As expected, the normal increase in p53 levels after exposure to ionizing radiation was moderately suppressed in human U2OS tumour cells transfected with a wildtype PPM1D expression construct, matching previous observations 16, 17 ( Fig. 3) . The suppression of p53 was enhanced in cells transfected with the mutant PPM1D expression constructs, suggesting that each of these alleles encodes a hyperactive PPM1D isoform, that is, consistent with a gain-of-function rather than loss-of-function effect (Fig. 3) . Similar effects were also observed in HeLa and 293 cells ( Supplementary Fig. 7) .
To investigate the mechanism of oncogenesis in PPM1D PTVmutation carriers we analysed eight tumours from five individuals. Intriguingly, the PPM1D mutations were not detectable in any of the tumours by Sanger sequencing or MLPA ( Supplementary Fig. 8 ).
Through microsatellite analysis we confirmed that the tumours were from the correct individuals and demonstrated loss of heterozygosity at the PPM1D locus in seven out of eight tumours, although there was no evidence of PPM1D copy number alteration ( Supplementary Fig. 8 and Supplementary Table 8 ). We microdissected stromal tissue from the ovarian tumour in four cases and undertook deep sequencing across the PPM1D PTV in blood, tumour and stromal DNA. Each mutation was present in the blood, at similar levels to that detected previously, absent from the tumour and either absent (two cases) or present at very low levels (5 out of 915 and 4 out of 5,793 reads) in the stroma, consistent with lymphocyte contamination (Supplementary Fig. 8 and Supplementary Table 5) .
These data are intriguing and strongly suggest the mechanism of cancer association in PPM1D-mutation carriers differs from that in carriers of mutations in other DNA repair genes associated with predisposition to these cancers. There are several potential explanations. It is possible the mutation was present in the cell of cancer origin but was subsequently lost, perhaps because a PPM1D mutation can act as a driver to initiate oncogenesis, but is not required, or is detrimental to the progression of the resulting cancer. The allele loss we observed at the PPM1D locus could be interpreted as supportive of this hypothesis, but it should be noted that it is not known if the lost allele carried the PPM1D PTV, and loss in this region of 17q is common in these cancers. Alternatively, the absence of the PPM1D mutation in the tumour could be because oncogenesis is being driven by the mutation in circulating blood cells. Another possibility is that the PPM1D mutations are not directly involved in causing breast or ovarian cancer. For example, they could be a separate manifestation of an underlying lesion, perhaps one that causes genomic instability, which can lead to selection and clonal expansion of cells with PPM1D PTVs and also to cancers in other tissues. Clearly, further studies will be required to explain the mechanism of oncogenesis in PPM1D-mutation carriers.
Irrespective of the mechanism of the association, our data demonstrate that individuals with mosaic PPM1D PTVs in the mutation cluster region are at increased risk of cancer. The association is not explicable by increasing age, unlike recently reported mosaic chromosomal abnormalities 27, 28 (Supplementary Table 5 ). To estimate the cancer risks we undertook a retrospective cohort analysis using information on breast and ovarian cancer occurrence in the 6,577 unrelated individuals negative for BRCA1/2 mutations and controls, by modelling the retrospective likelihood of the observed mutation status conditional on the disease phenotype, as previously described 9, 29 . This approach adjusts for our ascertainment of cases with more extreme phenotypes such as young age of onset or bilateral breast cancer, which we use to empower gene discovery [4] [5] [6] [7] 10, 30 . The relative risk of breast cancer for PPM1D PTV-mutation carriers was estimated to be 2.7 (95% confidence interval: 1.3-5.3; P 5 5.38 3 10
23
), which translates to approximately 23% cumulative risk by age 80. The relative risk of ovarian cancer was estimated to be 11.5 (95% confidence interval: 4.3-30.4; P 5 9.95 3 10
27
), which translates to approximately 18% cumulative risk by age 80. It is noteworthy that we sequenced an unselected hospital-based series of 322 patients with ovarian cancer in whom we identified five PPM1D PTVs, suggesting that 1-2% of patients with ovarian cancer may contain mosaic PPM1D mutations.
The frequency of PPM1D PTVs in BRCA1/2-mutation carriers with breast and/or ovarian cancer was also significantly different from population controls (4 out of 773 versus 1 out of 5,861; P 5 8.30 3 10
24
) and similar to that in cases of breast and/or ovarian cancer without BRCA1/ 2 mutations (4 out of 773 versus 21 out of 6,634; P 5 0.56), suggesting that PPM1D PTVs are also associated with increased risks of cancer in BRCA1/2-mutation carriers. Studies of unselected, population-based patients with cancer and of larger series of BRCA1/2-mutation carriers would be of value to extend our observations, and to explore further the prevalence and cancer risks associated with PPM1D mutations.
These data provide new insights into ovarian and breast cancer, potentially identifying a new class of genetic defect that lies somewhere between classic germline genetic predisposition mutations and tumourspecific somatic events. It is also highly plausible that PPM1D mutations are associated with other cancers, and broad evaluation of individuals with other tumour types would be of interest. More generally, the clinical implications of a mosaic cancer predisposition marker that is genetic, but not hereditary, and that is detectable in the blood but not the tumour(s) it is associated with are rather profound, particularly if this phenomenon is observed in other genes/contexts.
Our results also provide insights into genetic variation, particularly in relation to the nature and effect of rare gene mutations associated with disease. Given the truncating mutations we report probably have a gain-of-function effect, the widespread interchangeable use of the terms 'truncating mutation' and 'loss-of-function mutation' is inappropriate. We believe a more descriptive term such as 'protein-truncating variant', which does not imply the functional consequence of the mutation, is preferable. We also provide evidence that mosaic mutations can wild-type U2OS human osteosarcoma cells were transfected with PPM1D cDNA expression constructs and exposed to ionizing radiation (IR; 5 Gy). At 30 min and 4 h intervals whole-cell lysates were analysed by western blot to estimate the ionizing-radiation-induced activation of p53. Western blots showing p53 and actin (loading control) protein levels at different times (in hours) after ionizing radiation exposure are shown. cH2AX is a marker of DNA damage, including double-stranded DNA breaks. 'Empty' denotes transfection with empty construct. PPM1D WT denotes transfection with the wild-type PPM1D construct. PPM1D c.1384C.T and PPM1D c.1420delC denote transfection with mutant PPM1D constructs. Suppression of p53 was enhanced in cells transfected with mutant constructs, suggesting that these alleles encode hyperactive PPM1D isoforms.
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have relevance to common disease. Such variants are challenging to detect by Sanger sequencing, but are detectable by next-generation sequencing approaches. It is therefore likely that further examples of mosaic disease-associated mutations will be forthcoming, although studies to define the frequency and characteristics of mosaic mutations in control individuals will be essential, to ensure the implications of such variants in case series are correctly interpreted. Finally, although newer sequencing technologies are making large-scale whole-genome sequencing experiments ever more feasible, it is likely that focused sequencing experiments with tailored design and analytical prioritization strategies, such as those used here, will have utility over the next few years.
METHODS SUMMARY
Lymphocyte DNA from 8,046 individuals affected with breast and/or ovarian cancer and 5,861 population-based controls were included. A custom pull-down that included 507 genes (DNA repair panel) was designed using the Agilent SureSelect target enrichment system and sequenced in samples from 1,150 women, in pools of 24 samples, with an Illumina HiSeq2000. Sequence reads were mapped to the human reference genome (hg19) using BWA (version 0.5.6). Variant calling was undertaken with Syzygy 11 (version 1.2.4). Primers for PPM1D Sanger sequencing were designed using exon-primer. Amplicons were sequenced using the BigDye terminator cycle sequencing kit and an ABI3730 automated sequencer (ABI PerkinElmer). Deep PCR amplicon sequencing was undertaken by amplifying the PPM1D mutation cluster region, and BRCA1 and BRCA2 using a Multiplex PCR kit (Qiagen), preparing libraries with Nextera technology 11 and sequencing on an Illumina MiSeq. Sequencing of the DNA repair panel in indexed samples from six PPM1D PTVmutation carriers was undertaken using Illumina TruSeq kits for library preparation and an Illumina HiSeq2000. For these latter experiments, sequence reads were mapped using Stampy version 1.0.14 and variants were called with Platypus (http://www.well.ox.ac.uk/platypus). MLPA was undertaken using the SALSA MLPA probe mix P200 (MRC Holland). Microsatellite analysis was undertaken with 596-FAM tagged primer pairs. PCR products were run on a 3730xL genetic analyser (ABI PerkinElmer) and data were analysed using GeneMarker v1.51 (SoftGenetics). The U2OS, HeLa and HEK293 (p53 wild-type) cell lines were transfected with a plasmid containing full-length wild-type PPM1D cDNA and the PPM1D open reading frame subcloned into pCMV6-AN-HA (Origene), generating a construct that could express a PPM1D N-terminal haemagglutinin (HA) epitope fusion protein.
Mutations were introduced using the QuickChange II XL site-directed mutagenesis kit (Stratagene). Statistical analyses were performed using the statistics package in R. Cancer risks were estimated within a retrospective cohort analysis framework 9, 29 .
Full Methods and any associated references are available in the online version of the paper.
METHODS
Patients and samples. We used lymphocyte DNA from 8,046 individuals affected with breast and/or ovarian cancer that were recruited by two studies. There were 7,724 cases recruited through 24 genetics centres in the United Kingdom via the Breast and Ovarian Cancer Susceptibility (BOCS) study, which recruits women $18 years who have had breast cancer and/or ovarian cancer and have a family history of breast cancer and/or ovarian cancer. Each proband was screened for BRCA1 and BRCA2 mutations (by Sanger sequencing and/or heteroduplex analysis) and large rearrangements (by MLPA). The remaining 322 cases are an unselected hospital-based series of women with ovarian cancer who were recruited during treatment for ovarian cancer at the Royal Marsden Hospital. The DNA was extracted from peripheral blood samples except in 11 cases, for which DNA was extracted from a lymphoblastoid cell line (note that all of the PPM1D mutations were identified in peripheral blood-derived DNA). At least 97% of families were of European ancestry, that is, comparable to the controls. Informed consent was obtained from all participants. The research was approved by the London Multicentre Research Ethics Committee (MREC/01/2/18).
For the phase 1 pooled DNA repair panel experiment we used lymphocyte DNA from 1,150 women with breast cancer, of which 69 also had ovarian cancer. Seventy-eight of these individuals had one mutation, and one individual had two mutations, in known cancer predisposition genes. These were included as positive controls to evaluate variant calling (see below). For the PPM1D casecontrol sequencing experiment we used 7,781 individuals with breast and/or ovarian cancer. We did not use the case data from the pooled DNA repair panel experiment in the case-control analysis, first because the mutation status of individuals cannot be definitively obtained from the pooled experiment as one cannot be certain that every sample is equally represented in a pool, and second because the mutation detection method was different to that used in the case-control experiment. We used our standard case and control sample trays for the casecontrol PPM1D sequencing experiment and the sample selection was blind to the pooled DNA repair panel experiment. There were 885 individuals that were part of both experiments. Samples and pathology information from mutation-positive families. For families in which a PPM1D mutation was detected, we sought DNA samples from relatives. We also requested tumour material, histopathology information and immunohistochemical profiles, including hormone receptor and HER2 status for patients with breast cancer, in probands from the hospitals where they had been treated. Representative tumour blocks were retrieved where possible and examined by two histopathologists, and classified and graded according to the World Health Organization 2003 classification 31, 32 . Tumours were microdissected under a stereomicroscope and genomic DNA was extracted from tumours and, where possible, stroma using the DNeasy kit (Qiagen) as previously described 32 . Controls. We used lymphocyte DNA from 5,861 population-based controls obtained from the 1958 Birth Cohort Collection, a continuing follow-up of persons born in the United Kingdom in one week in 1958. Biomedical assessment was undertaken during 2002-2004 at which blood samples and informed consent were obtained for creation of a genetic resource but phenotype data for these individuals is not available. At least 97% of the controls were of European ancestry (http:// www.cls.ioe.ac.uk/page.aspx?&sitesectionid5724&sitesectiontitle5Welcome1to 1the119581National1Child1Development1Study). DNA repair panel sequencing. We identified genes for inclusion on the DNA repair panel from the Gene Ontology (GO) database (http://www.geneontology. org/) using the search term 'DNA repair' (GO accession 0006281) and from STRING (http://string-db.org/) by identifying all genes interacting with ATM, BRCA1, BRCA2, BRIP1, CHEK2 and PALB2 with highest confidence ($0.9). This data set was manually curated to remove duplicate genes and pseudogenes. Consensus CoDing Sequence (CCDS) transcripts for the remaining genes were retrieved from UCSC Genome Browser (http://genome.ucsc.edu/, from November 2010) (Supplementary Table 2 ). Genomic coordinates for all coding exons were identified and targeted in a custom pull-down designed using the Agilent SureSelect target enrichment system 33 . We created 48 pools of DNA that each included 4 ml of 50 ng ml 21 of DNA (that is, 200 ng) from 24 individuals. We sheared 80 ml of the pooled DNA using Covaris technology. We prepared libraries without gel size selection or PCR enrichment using the Illumina genomic PE sample prep kit (Ilumina) and performed target enrichment according to the Agilent SureSelect protocol. Sequencing was performed by the Wellcome Trust Centre for Human Genetics high-throughput DNA sequencing and MRC hub in Oxford on an Illumina HiSeq2000 (v2 flow cell, one lane of sequencing per pool) generating 2 3 100-bp reads. Sequence reads for each pool were mapped to the human reference genome (hg19) using BWA (version 0.5.6) 34 . Mapped reads were filtered to remove ambiguous alignments with a quality score of 0 and bases with a call quality below 22 were masked. Of the remaining reads for each pool, 50-60% fell within the target regions, except for pool 21 in which the on-target percentage was significantly lower.
Median coverage for each pool achieved for target regions after filtering was between 2,8493 and 5,5453. This corresponded to an average coverage of 119-2313 per sample. All pools had 90% of the target covered at a minimum of 4803. Target regions within the MHC achieved substantially lower coverage and were excluded from further analysis.
We also sequenced the DNA repair panel in six PPM1D PTV-positive individuals using Illumina TruSeq kits for library preparation to enable sample indexing. Genomic DNA (1.5 mg) was fragmented and the libraries prepared using the Illumina TruSeq sample preparation kit (index set A). One pool of six libraries (500 ng each) was enriched as before but with the addition of extra blocking primers targeted against the TruSeq index adaptor sequences. Sequencing was performed at the Institute of Cancer Research with an Illumina HiSeq2000 (v3 flow cell, one lane) generating 2 3 100-bp reads. Mapped reads were filtered to remove ambiguous alignments with a quality score of 0 and bases with a call quality below 22 were masked. Of the remaining reads, 41-43% fell within the target region for each individual. Median coverage of the target for each individual after filtering was between 6023 and 6903. All individuals had 90% of the target covered at a minimum of 503. PPM1D Sanger sequencing. We designed primers to PCR-amplify and Sangersequence PPM1D using exon-primer from the UCSC genome browser (http:// genome.ucsc.edu/, from November 2010). Primers and conditions are available on request. PCR reactions were performed using the Qiagen multiplex PCR kit. Amplicons were unidirectionally sequenced using the BigDye terminator cycle sequencing kit and an ABI3730 automated sequencer (ABI PerkinElmer). We analysed the full coding sequence in 2,456 cases and 1,347 controls. As all of the mutations identified in these samples were restricted to exon 6 we sequenced the mutation cluster region (c.1261-20-c.1695), but not the rest of the gene, in the remaining 5,325 cases and 4,514 controls. We also sequenced the mutation cluster region in all available samples from relatives of PPM1D PTV-positive probands. All sequencing traces were independently analysed by two individuals who were blinded to the others analysis. Each individual analysed the sequencing with both automated software (Mutation Surveyor, SoftGenetics) and manual visual inspection. All putative mutations were confirmed by bidirectional sequencing from a fresh aliquot of the stock DNA. We also undertook Sanger sequencing of the PPM1D cluster region, in triplicate, in DNA from eight tumour samples and four ovarian stromal samples.
For the cDNA sequencing we established lymphoblastoid cell lines from three individuals with PPM1D PTVs (cases 20, 23 and 24). RNA was extracted using the RNeasy minikit (Qiagen) and cDNA synthesized using the ThermoScript RT-PCR system (Invitrogen), using standard protocols. We amplified the mutation cluster region using a cDNA-specific primer (forward, 59-ACCACCAGTCAAGT CACTGG-39, reverse, 59-TCTTTCGCTGTGAGGTTGTG-39), which we sequenced as described above. Deep PCR amplicon sequencing. In lymphocyte DNA we amplified the PPM1D mutation cluster region and the full coding sequence and intron-exon boundaries of BRCA1 and BRCA2 using the multiplex PCR kit (Qiagen). We prepared indexed libraries of the PCR products using Nextera technology (Ilumina) 13 . We created two pools of 24 indexed libraries that we sequenced using an Illumina MiSeq, generating 2 3 150-bp reads. Data from 20 individuals passed quality control coverage metrics, generating median coverage greater than 5003 across the PPM1D cluster region (average median coverage 3,3843).
For the tumour analyses we amplified the mutation cluster region in tumour, stroma and blood DNA using an Illumina Nextera XT library preparation kit and supplied protocol (Illumina). To attain the required 1 ng input for tagmentation we also amplified BRCA1 in 24 samples as described above and we then created one pool of 24 indexed libraries that we sequenced using an Illumina MiSeq, generating 2 3 150-bp reads. We visually inspected all sequencing reads present at the mutation site after alignment with Stampy to determine whether the PPM1D mutation was present. DNA repair panel data. For the pooled DNA repair panel analysis, variant calling was undertaken with Syzygy (version 1.2.4) 11 . We successfully identified 402 out of 439 previously validated single nucleotide polymorphisms (SNP) with a minor allele frequency (MAF) . 5% genotyped through a breast cancer genome-wide association study (GWAS) 35 with high confidence, and the remaining 37 SNPs were detected at lower confidence. Syzygy also detected 75 out of 80 rare variants (MAF , 1%) included in the study as positive controls (24 out of 26 base substitutions, 14 out of 14 insertions, 30 out of 32 deletions, and 7 out of 8 complex indels; Supplementary Table 3) . Thus, sensitivity was 99.6% for base substitutions and 94.4% for rare indels. Frequency estimation for rare variants was assessed by evaluation of 39 BRCA1 and BRCA2 variants at a frequency of one per pool. Syzygy correctly estimated the frequency in 33 of the 35 variants it detected, incorrectly estimating the frequency at two per pool for the remaining two variants. Deep PCR amplicon sequencing data. For the deep PCR amplicon sequencing and the indexed DNA repair panel sequencing in six individuals, sequence reads were LETTER RESEARCH mapped to the human reference genome (hg19) using Stampy version 1.0. 14 (ref. 36) . Duplicate reads were flagged using Picard version 1.60 (http://picard.sourceforge.net). Variant calling was performed with Platypus version 0.1.9 (http://www.well.ox.ac.uk/ platypus) 37 . The mutant read percentage was calculated as the proportion of total reads at the variant location that contained the variant, with a minimum mutant read percentage threshold of 5%. Variant annotation. Annotation for all experiments was undertaken with reference to CCDS transcripts from Ensembl version 65 identified using a custom Perl script (Supplementary Table 2 ). Variant calls were annotated for changes with respect to the chosen transcript and assigned a consequence type from the list used by Ensembl. PTV prioritization method. This is a gene-based (rather than the more typical variant-based) strategy that aims to prioritize potential disease-associated genes for follow-up by leveraging two properties of protein truncating variants: (1) the strong association of rare truncating variants with disease, and (2) collapsibility. Different PTVs within a gene typically result in the same functional effect and can be combined equally. We implemented the method using the statistics package in R. We first outputted all the predicted protein truncating variants: stop gains, coding frameshifts and essential splice site variants (22, 21, 11, 12 and 15) . For this experiment we defined 'rare' as PTVs that were seen only once in the DNA repair panel data. We next stratified the genes according to the number of different, rare singleton PTVs called. We excluded genes for which samples had been included as positive controls (Supplementary Table 3 ). PPM1D was the top gene in this analysis. We are undertaking further analyses and follow-up of the DNA repair panel data, which we aspire to present in a separate publication. MLPA. We designed 22 probe pairs targeting PPM1D PTVs (n 5 18), wild-type PPM1D (n 5 2), wild-type BRCA1 (n 5 1) and wild-type CEP112 (n 5 1) (Supplementary Table 7 ). We added the synthetic probes to the SALSA MLPA probe mix P200 (MRC Holland). MLPA reactions were performed in triplicate according to the manufacturer's instructions. MLPA was undertaken in lymphocyte DNA from 17 probands and in eight tumour DNA samples (from five individuals). In brief, probes were hybridized to 150 ng of denatured DNA, amplified by PCR, and separated on an ABI 3130 genetic analyzer (Applied Biosystems). Data were analysed using GeneMarker v1.51 software (SoftGenetics). Microsatellite analysis. We used 596-FAM tagged primer pairs and PCR conditions for 17q microsatellite analysis as listed in Supplementary Table 8 . Ten microlitres of a mastermix of 30 ml ROX size standard and 1 ml HiDi formamide were added to each reaction post PCR, denatured at 95 uC for 5 min, and cooled at 220 uC for 5 min. Reactions were run on a 3730xL genetic analyser (Applied Biosystems) under the fragment analysis protocol. Data were analysed using GeneMarker v1.51 software (SoftGenetics). Microsatellite analysis was undertaken in lymphocyte DNA from 13 individuals from eight families, and in eight tumour DNA samples and four stroma DNA samples from five individuals. Of note, one of these cases (case 17) contained both BRCA1 and PPM1D mutations. Both genes are located at chromosome 17q and it is the wild-type BRCA1 allele that is reduced in the tumours and therefore the relevance of the loss of heterozygosity with respect to PPM1D is difficult to deduce. Cell line and plasmid constructs. The U2OS, HeLa and HEK293 (all p53 wildtype) cell lines were obtained from the American Type Culture Collection (ATCC). Cells were cultured and maintained according to the supplier's instructions. Cells were transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen). A plasmid containing full-length wild-type PPM1D cDNA (pCMV6 entry-PPM1D) was obtained from Origene, and the PPM1D open reading frame (ORF) subcloned into pCMV6-AN-HA (Origene), generating a construct that could express a PPM1D N-terminal haemagglutinin (HA) epitope fusion protein. Truncating mutations were introduced into the PPM1D ORF of this construct using the QuickChange II XL site-directed mutagenesis kit (Stratagene). The following DNA amplication primers were used: PPM1D mutant 1 (c.1384C.T): forward, 59-AGAGAATGTCTAAGGTGTAGTC-39, reverse, 59-GACTACACCTTAGACA TTCTCTC-39; PPM1D mutant 2 (c.1420delC): forward, 59-GATCCAGAACCA TTGAAG-39, reverse, 59-CTTCAATGGTTCTGGATC-39. Western blot analysis of p53 levels. U2OS, HeLa and HEK293 cells were transfected with PPM1D expression constructs, and 24 h after transfection, cells were exposed to c-irradiation (5 Gy) from an X-ray source. Whole cell lysates were generated from transfected cells after irradiation (at 30 min and 4 h time points) and subjected to protein electrophoresis. Immunoblotting of electrophoresed lysates was performed using antibodies specific for p53 (9282S, Cell Signaling Technology) and actin (sc-1616, Santa Cruz Biotech). Frequency and risk estimation. Statistical analyses were performed using the statistics package in R. The significance of mutation clustering was modelled under a binomial distribution in which the probability of observing a mutation in the last exon, which comprises 31% of the coding sequence, was 0.31. The frequency in BRCA1/BRCA2-mutation carriers and non-carriers was compared using a twosided test of proportions. Risk estimation was implemented using a competing risks retrospective likelihood model incorporating age at onset according to a proportional hazards model. Because individuals screened for PPM1D mutations were selected on the basis of both personal and family history of breast or ovarian cancer, standard methods of analysis that ignore the sampling frame would yield biased estimates of the risk ratios. To address this, we analysed data within a retrospective cohort approach by modelling the conditional likelihood of the observed genotypes given the disease phenotypes, using information on breast and ovarian cancer occurrence in the set of 6,577 unrelated individuals negative for BRCA1/2 mutations (BRCA1/2 mutation-positive individuals from the BOCS series and all the unselected ovarian case series were excluded) and controls. Male controls were included in the analysis, but were not considered to be at risk of developing breast or ovarian cancer. We assumed a competing risks model, under which, each individual was at risk of developing breast or ovarian cancer. This has been shown to provide unbiased estimates of the risk ratios for breast and ovarian cancer in which a genetic variant may be associated with one or both of the diseases 29 . We estimated the PPM1D-mutation carrier frequency in the population and breast and ovarian cancer risk ratios simultaneously. Because mutation screened probands may have been selected on the basis of bilateral breast cancer diagnosis or on the basis of both breast and ovarian cancer diagnosis we allowed for the risks of breast or ovarian cancer diagnosis after the first cancer diagnosis, including the risk of contralateral breast cancer. This model assumes that the increased breast cancer (including contralateral) or ovarian cancer risk after the first cancer diagnosis is entirely due to the susceptibility as defined by the model, with no other variation in risk. Site-specific cancer risks were assumed to be independent conditional on genotype. Therefore, the incidence of cancer at the second site was assumed to be the same as if the preceding cancer had not occurred, with the exception of contralateral breast cancer incidence after the first breast cancer, which was assumed to be half the overall breast cancer incidence, as only one breast was at risk. In all models females were censored at age 80 years. We assumed that the breast and ovarian cancer incidences depend on the underlying PPM1D genotype through models of the form: l(t)~l 0 (t) exp (bx), in which l 0 (t) is the baseline incidence at age t in non-mutation carriers, b is the log-risk ratio associated with the mutation, and x takes value 0 for non-mutation carriers and 1 for mutation carriers. The overall breast and ovarian cancer incidences, over all genotypes, were constrained to agree with the population incidences for England and Wales in the period of 1993-1997 (ref. 38), as described previously 30, 39 . The models were parameterized in terms of the mutation frequencies and log-risk ratios for breast and ovarian cancer. Parameters were estimated using maximum likelihood estimation and were implemented in the pedigree analysis software MENDEL 40 . The variances of the parameters were obtained by inverting the observed information matrix. To obtain confidence intervals for the risk ratios and perform hypothesis testing, log-risk ratios were assumed to be normally distributed. A Wald teststatistic was used to test the null hypothesis that b 5 0 for both breast and ovarian cancer. Because PPM1D mutations were not found to segregate within families, we did not take into account precise family histories or pedigree information and therefore did not incorporate the effects of other susceptibility genes.
